gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ICCCHealthcareDiagnostics

Immucell Corp (ICCC)

$10.37+1.17%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.16▲ 63.61% in range
Nov 3, 2025Low $4.56 · High $11.72Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Immucell closed at $10.37 on Nov 4, up 1.17%, 11.5% below its 52-week closing high. Volume of 5.7K shares was 0.70× its 20-day average (below normal).

Split-adjusted performance: +4.0% over one month, +19.7% over six months, +67.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.19M, up 11.5% from a year earlier, with a net margin of 25.5%.

Short interest was 18.1K shares at the Oct 15 settlement, down 18.1% from the prior report (0.3% of float, 1.4 days to cover).

Market cap$94.2M9.1M shares
Revenue · quarter$7.2M+11.5% YoY
Diluted EPS$0.20+233.3% YoY
P/E · TTM119.6×P/S 3.1×
Net margin25.5%Gross 33.9%
Dividend yieldNone
52-week range4.56 – 11.72−11.5% from high
Volume5.7K0.70× 20-day avg
Volatility · 60d38.4%Annualised
Short % of float0.3%1.4 days to cover
Net cash$557.3KCash $8.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.4%1M +4.0%3M −5.9%6M +19.7%YTD +68.6%1Y +67.0%3Y +110.3%5Y +16.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum57
Revenue growth92
Net margin92
Value (low P/E)—
Size36

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short18.1K−18.1% vs prior
Days to cover1.4Settled Oct 15
% of float0.3%
Short vol. 10d38.7%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ICCCImmucell$10.37+1.17%+19.7%+11.5%25.5%119.6$94.2M
IMDXInsight Molecular Diagnostics$2.65−3.28%−47.3%−53.9%−4711.3%—$86.7MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
BMRABIOMERICA$1.74+2.06%−21.5%−8.3%−97.4%—$8.0MCompare
VNRXVolitionRx Limited$0.2031+5.23%−91.8%−2.0%−1953.1%—$6.1MCompare
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72BCompare

News about Immucell

All news →
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?Zacks Investment Research · Oct 21, 2026▲ PositiveImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2Zacks Investment Research · Aug 27, 2026Neutral

Quick answers

What does Immucell do?
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components.
What is ICCC's market cap?
$94.18M, based on the Nov 4 close of $10.37.
What is ICCC's P/E ratio?
119.6× trailing-twelve-month earnings of $787.37K.
Does Immucell pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ICCC is sold short?
18.1K shares, 0.3% of float, as of Oct 15, 2026.
What sector is ICCC in?
Healthcare, in the Diagnostics industry.

About Immucell

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

HQ: Portland, ME73 employeesListed Jul 8, 1987immucell.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology